Nuvectis Pharma, Inc. NVCT Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvectis Pharma, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvectis Pharma, Inc.'s additional paid-in capital?
- Nuvectis Pharma, Inc. (NVCT) reported additional paid-in capital of $119.96M in Q1 2026.
- How has Nuvectis Pharma, Inc.'s additional paid-in capital changed year-over-year?
- Nuvectis Pharma, Inc.'s additional paid-in capital increased by 20.5% year-over-year, from $99.53M to $119.96M.
- What is the long-term trend for Nuvectis Pharma, Inc.'s additional paid-in capital?
- Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s additional paid-in capital has grown at a 181.1% compound annual growth rate (CAGR), from $1.89M to $118.1M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.